Jump to content
Sign in to follow this  

Cannabis-based medicine launched in UK

Recommended Posts


Analysts predict between £50m and £60m of peak annual sales for Sativex by 2015, with GW receiving between 20 and 30 per cent of that.

The approval of Sativex provides a boost to GWÂ’s development programme to create other cannabis-based medicines. Trials are already underway on cannabis-based medicines to treat epilepsy and psychosis, and GW is seeking approval from US regulators for the marketing of Sativex as a treatment for cancer pain


Share this post

Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
Sign in to follow this